Science Translational Medicine reports that a new drug originally developed for type 2 diabetes is being prepared for human clinical trials in hope of finding the world's first treatment to slow Parkinson's disease.
The drug was developed by Kalamazoo-based Metabolic Solutions Development Company and supported by research from Van Andel Research Institute's Center for Neurodegenerative Science.
Re
Asthma affects an estimated 300 million people worldwide and about half of all asthmatics suffer from allergic asthma.
A new drug for sufferers of allergic asthma is showing early signs of success in testing.